Skip to main content

Advertisement

Table 3 Meta-regression and subgroup analyses of pooled hazard ratios for progression-free survival

From: Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis

Subgroup Meta-regression Pooled HR of PFS Heterogeneity
No. of studies Coefficient Standard error T value P value Tau2 Adjusted R2 HR (95% CI) P value I2 P value
Year 20 0.060 0.228 0.26 0.795 0.182 −8.86%     
 2011–2014         0.56 (0.40–0.77) <0.001 83.00% <0.001
 2015–2017         0.61 (0.48–0.77) <0.001 73.60% <0.001
Sample size 20 0.507 0.197 2.57 0.019 0.122 27.34%     
 <200         0.43 (0.30–0.61) <0.001 72.10% <0.001
 ≥200         0.73 (0.60–0.89) 0.002 75% <0.001
Gender (male/female ratio) 20 −0.117 0.228 −0.51 0.614 0.177 −5.64%     
 <2.5         0.66 (0.53–0.82) <0.001 54.50% 0.025
 ≥2.5         0.55 (0.40–0.74) <0.001 84.70% <0.001
Mean age 20 0.320 0.264 2.21 0.241 0.156 6.69%     
 <60         0.44 (0.23–0.86) 0.015 89.40% <0.001
 ≥60         0.64 (0.53–0.78) <0.001 69.70% <0.001
Country 20 0.168 0.301 0.56 0.584 0.173 −3.31%     
 the USA, Europe         0.60 (0.49–0.74) <0.001 81.40% <0.001
 Asia         0.51 (0.31–0.83) 0.006 39.50% 0.158
ECOG PS (grade 0%) 20 0.036 0.133 0.27 0.79 0.182 −8.59%     
 <0.5         0.35 (0.14–0.89) 0.028 87.20% <0.001
 ≥0.5         0.64 (0.52–0.79) <0.001 71.90% <0.001
MSKCC score (favorable%) 20 0.231 0.111 2.08 0.052 0.123 26.74%     
 <0.25         0.43 (0.21–0.87) 0.019 76% 0.002
 ≥0.25         0.86 (0.73–1.02) 0.076 40.30% 0.137
Histology (clear cell%) 20 −0.139 0.126 −1.11 0.283 0.166 1.11%     
 <0.9         0.53 (0.39–0.71) <0.001 29.30% 0.226
 ≥0.9         0.51 (0.33–0.79) 0.002 87.90% <0.001
Prior nephrectomy (%) 20 −0.162 0.129 −1.25 0.226 0.166 1.16%     
 <0.9         0.52 (0.40–0.67) 0.296 17.50% <0.001
 ≥0.9         0.52 (0.33–0.81) <0.001 89.30% 0.005
No. of disease sites (1%) 20 −0.253 0.139 −1.81 0.086 0.144 13.81%     
 <0.2         0.41 (0.28–0.60) <0.001 62.40% 0.047
 ≥0.2         0.52 (0.37–0.74) <0.001 0 0.594
Type of analysis 20 −0.030 0.231 −0.13 0.898 0.182 −8.91%     
 Univariate         0.59 (0.42–0.82) 0.002 82.70% <0.001
 Multivariate         0.58 (0.46–0.75) <0.001 74.50% <0.001
Study design 20 0.343 0.257 1.34 0.198 0.157 6.32%     
 Retrospective         0.54 (0.44–0.67) <0.001 74.90% <0.001
 Prospective         0.77 (0.53–1.12) 0.175 76.20% 0.006
Type of TKIs 20 −0.073 0.114 −0.64 0.942 0.178 −10.49%     
 Axitinib         0.70 (0.48–1.03) 0.07 80.90% 0.001
 Sorafenib         0.86 (0.65–1.13) 0.277 0 0.339
 Sunitinib         0.47 (0.34–0.64) <0.001 77.90% <0.001
 Pazopanib         0.79 (0.66–0.94) 0.010 0 1.000
  1. No. number, HR hazard ratio, PFS progression-free survival, ECOG PS Eastern Cooperative Oncology Group performance status, MSKCC score Memorial Sloan Kettering Cancer Center score